乳腺癌预后临床病理分子指标的研究进展  

Research progress of clinicopathologic molecular indicators of breast can cer prognosis

作　　者：黎骋 LI Cheng(Department of Pathology,Wuzhou Red Cross Hospital,Wuzhou Guangxi 543002)

机构地区：[1]梧州市红十字会医院病理科,广西梧州543002

出　　处：《当代医药论丛》2023年第16期12-16,共5页

基　　金：梧州市科学计划项目,合同编号:201902131。

摘　　要：乳腺癌是一组异质性非常大的恶性肿瘤,不同类型乳腺癌在临床表现、生物学行为和对治疗的反应上有显著差异。在过去的几十年里,乳腺癌的分类和预后预测主要基于临床病理(即形态学、大小、分级、淋巴结状态等)。但即使是在免疫表型相似的肿瘤中,这些特征也并不是总能提供准确的预后预测信息。随着近年来分子基因学研究的深入,发现通过对疾病的临床病理分子指标进行探究,能为疾病的预后预测提供新思路。本文主要是分析乳腺癌预后临床病理分子指标的研究现状,探究临床病理分子指标对疾病预后的影响,为疾病的临床治疗提供相应的参考依据。Breast cancer is a group of very heterogeneous malignant tumors.Different types of breast cancer have significant differences in clinical manifestations,biological behavior and response to treatment.In the past few decades,the classification and prognosis of breast cancer has been based mainly on clinicopathology(i.e.morphology,size,grade,lymph node status,etc.).But even in immunophenotypically similar tumors,these features do not always provide accurate prognostic information.With the deepening of molecular genetics research in recent years,it is found that the exploration of clinical pathological molecular indexes of diseases can provide a new way to predict the prognosis of diseases.This paper mainly analyzes the current research status of clinicopathological molecular indicators of breast cancer prognosis,explores the influence of clinicopathological molecular indicators on disease prognosis,and provides corresponding reference for clinical treatment of the disease.

关 键 词：乳腺癌 临床病理 分子指标 预后 研究进展 

分 类 号：R73[医药卫生—肿瘤]